Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $37.0 million.

  • Ultragenyx Pharmaceutical's Share-based Compensation fell 1096.73% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.7 million, marking a year-over-year increase of 271.88%. This contributed to the annual value of $158.1 million for FY2024, which is 1688.2% up from last year.
  • Ultragenyx Pharmaceutical's Share-based Compensation amounted to $37.0 million in Q3 2025, which was down 1096.73% from $38.6 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Share-based Compensation peaked at $41.6 million during Q3 2024, and registered a low of $24.3 million during Q1 2021.
  • For the 5-year period, Ultragenyx Pharmaceutical's Share-based Compensation averaged around $33.9 million, with its median value being $34.9 million (2023).
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Share-based Compensation skyrocketed by 3268.77% in 2021, and later tumbled by 1096.73% in 2025.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Share-based Compensation stood at $26.5 million in 2021, then grew by 10.57% to $29.4 million in 2022, then rose by 14.95% to $33.7 million in 2023, then grew by 19.1% to $40.2 million in 2024, then dropped by 7.91% to $37.0 million in 2025.
  • Its Share-based Compensation was $37.0 million in Q3 2025, compared to $38.6 million in Q2 2025 and $39.9 million in Q1 2025.